{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:33Z","timestamp":1792788333645,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade Federal Do Rio De Janeiro","id":[{"id":"https:\/\/ror.org\/03490as77","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03393-8","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:12:51Z","timestamp":1779491571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Study of Rotigotine Release and Permeation from the Neupro\u00ae Transdermal Patch: An In Vitro-In Vivo Correlation"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2366-5422","authenticated-orcid":false,"given":"Thamara","family":"de Carvalho Mendes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1204-1905","authenticated-orcid":false,"given":"Hellen Regina Oliveira","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4550-5729","authenticated-orcid":false,"given":"Lucio Mendes","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-6182","authenticated-orcid":false,"given":"Alice","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1589-0846","authenticated-orcid":false,"given":"Valeria Pereira","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"3393_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40265-015-0377-y","volume":"75","author":"JP Elshoff","year":"2015","unstructured":"Elshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson\u2019s disease and restless legs syndrome. Drugs. 2015;75:487\u2013501.","journal-title":"Drugs"},{"key":"3393_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","volume":"379","author":"D Scheller","year":"2009","unstructured":"Scheller D, Ullmer C, Berkels R, Gwarek M, L\u00fcbbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson\u2019s disease. Naunyn-Schmiedebergs Arch Pharmacol. 2009;379:73\u201386.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"3393_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2023.121532","author":"D Yi","year":"2023","unstructured":"Yi D, et al. Analysis of the dissolution behavior and solubility of Rotigotine form II in different mono-solvents. J Mol Liq. 2023. https:\/\/doi.org\/10.1016\/j.molliq.2023.121532.","journal-title":"J Mol Liq"},{"key":"3393_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jaoacint\/qsaa145","volume":"104","author":"TdeC Mendes","year":"2021","unstructured":"Mendes TdeC, Pinto EC, Cabral LM, De Sousa VP. Rotigotine: a review of analytical methods for the raw material, pharmaceutical formulations, and its impurities. J AOAC Int. 2021;104:592\u2013604.","journal-title":"J AOAC Int"},{"key":"3393_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ejpb.2014.08.007","volume":"88","author":"DA McAfee","year":"2014","unstructured":"McAfee DA, Hadgraft J, Lane ME. Rotigotine: the first new chemical entity for transdermal drug delivery. Eur J Pharm Biopharm. 2014;88:586\u201393.","journal-title":"Eur J Pharm Biopharm"},{"key":"3393_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nrd2087","volume":"5","author":"AHV Schapira","year":"2006","unstructured":"Schapira AHV, et al. Novel pharmacological targets for the treatment of Parkinson\u2019s disease. Nat Rev Drug Discov. 2006;5:845\u201354.","journal-title":"Nat Rev Drug Discov"},{"key":"3393_CR7","unstructured":"European Medicines Agency. Annex I: Summary of product Characteristics. (2009). https:\/\/ec.europa.eu\/health\/documents\/community-register\/2009\/2009122369869\/anx_69869_en.pdf."},{"key":"3393_CR8","unstructured":"Wolff HM, Quere L, Riedner J. Polymorphic Form of Rotigotine and Process for Production. U.S. Patent 8,232,414 B2; 2012."},{"key":"3393_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ncl.2013.04.012","volume":"31","author":"C Waters","year":"2013","unstructured":"Waters C. The development of the rotigotine transdermal patch. A historical perspective. Neurol Clin. 2013;31:37\u201350.","journal-title":"Neurol Clin"},{"key":"3393_CR10","unstructured":"U.S. Food and Drug Administration. SUPAC-SS: Nonsterile Semisolid Dosage Forms\u2014Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation. Documentation [Internet]. 1997. https:\/\/www.fda.gov\/media\/71141\/download."},{"key":"3393_CR11","unstructured":"U.S. Food and Drug Administration. Guidance for Industry - Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations. Documentation [Internet]. 1997. https:\/\/www.fda.gov\/media\/70939\/download."},{"key":"3393_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1208\/pt040107","volume":"4","author":"M Siewert","year":"2003","unstructured":"Siewert M, Dressman J, Brown C, Shah V. FIP\/AAPS guidelines for dissolution\/in vitro release testing of novel\/special dosage forms. AAPS PharmSciTech. 2003;4:6\u201315.","journal-title":"AAPS PharmSciTech"},{"key":"3393_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijpharm.2006.10.001","volume":"328","author":"S Azarmi","year":"2007","unstructured":"Azarmi S, Roa W, L\u00f6benberg R. Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharm. 2007;328:12\u201321.","journal-title":"Int J Pharm"},{"key":"3393_CR14","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1208\/s12249-017-0738-9","volume":"18","author":"A Simon","year":"2017","unstructured":"Simon A, Amaro MI, Healy AM, Cabral LM, de Sousa VP. Development of a discriminative in vitro release test for rivastigmine transdermal patches using pharmacopeial apparatuses: USP 5 and USP 6. AAPS PharmSciTech. 2017;18:2561\u20139.","journal-title":"AAPS PharmSciTech"},{"key":"3393_CR15","unstructured":"U.S. Pharmacopeial Convention. Drug Release; in United States Pharmacopeia and National Formulary (USP 48\u2013NF 43); U.S. Pharmacopeial Convention: Rockville, MD; 2025."},{"key":"3393_CR16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/1523-1747.ep12533356","volume":"64","author":"TJ Franz","year":"1975","unstructured":"Franz TJ. Percutaneous absorption. On the relevance of in vitro data. J Invest Dermatol. 1975;64:190\u20135.","journal-title":"J Invest Dermatol"},{"key":"3393_CR17","unstructured":"European Medicines Agency. Guideline on Quality of Transdermal Patches; EMA\/CHMP\/QWP\/608924\/2014; European Medicines Agency: London, U.K.; 2014. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-transdermal-patches_en.pdf."},{"key":"3393_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ejps.2013.02.020","volume":"50","author":"D Karadzovska","year":"2013","unstructured":"Karadzovska D, Riviere JE. Assessing vehicle effects on skin absorption using artificial membrane assays. Eur J Pharm Sci. 2013;50:569\u201376.","journal-title":"Eur J Pharm Sci"},{"key":"3393_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/aivt.2015.0003","volume":"1","author":"C Dumont","year":"2015","unstructured":"Dumont C, Prieto P, Asturiol D, Worth A. Review of the availability of in vitro and in silico methods for assessing dermal bioavailability. Appl In Vitro Toxicol. 2015;1:147\u201364.","journal-title":"Appl In Vitro Toxicol"},{"key":"3393_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ijpharm.2018.06.012","volume":"547","author":"A Haq","year":"2018","unstructured":"Haq A, Goodyear B, Ameen D, Joshi V, Michniak-Kohn B. Strat-M\u00ae synthetic membrane: permeability comparison to human cadaver skin. Int J Pharm. 2018;547:432\u20137.","journal-title":"Int J Pharm"},{"key":"3393_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.slast.2021.12.006","volume":"27","author":"I Pulsoni","year":"2022","unstructured":"Pulsoni I, et al. Comparison between Franz diffusion cell and a novel micro-physiological system for in vitro penetration assay using different skin models. SLAS Technol. 2022;27:161\u201371.","journal-title":"SLAS Technol"},{"key":"3393_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1016405506028","volume":"4","author":"WJ Addicks","year":"1987","unstructured":"Addicks WJ, Flynn GL, Weiner N. Validation of a flow-through diffusion cell for use in transdermal research. Pharm Res. 1987;4:337\u201341.","journal-title":"Pharm Res"},{"key":"3393_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0168-3659(99)00276-X","volume":"66","author":"P Clement","year":"2000","unstructured":"Clement P, Laugel C, Marty J-P. Influence of three synthetic membranes on the release of caffeine from concentrated W\/O emulsions. J Control Release. 2000;66:243\u201354.","journal-title":"J Control Release"},{"key":"3393_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijpharm.2004.05.011","volume":"281","author":"GG Agyralides","year":"2004","unstructured":"Agyralides GG, Dallas PP, Rekkas DM. Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques. Int J Pharm. 2004;281:35\u201343.","journal-title":"Int J Pharm"},{"key":"3393_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejps.2014.11.002","volume":"67","author":"T Uchida","year":"2015","unstructured":"Uchida T, Kadhum WR, Kanai S, Todo H, Oshizaka T, Sugibayashi K.\u00a0Prediction of skin permeation by chemical compounds using the artificial membrane, Strat-M\u2122. Eur J Pharm Sci. 2015;67:113\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"3393_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ijpharm.2016.08.052","volume":"512","author":"A Simon","year":"2016","unstructured":"Simon A, Amaro MI, Healy AM, Cabral LM, de Sousa VP. Comparative evaluation of rivastigmine permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with in vivo-in vitro correlation. Int J Pharm. 2016;512:234\u201341.","journal-title":"Int J Pharm"},{"key":"3393_CR27","doi-asserted-by":"publisher","unstructured":"U.S. Pharmacopeial Convention. Rotigotine Transdermal System; USP 43\u2013NF 38; U.S. Pharmacopeial Convention: Rockville, MD; 2025. https:\/\/doi.org\/10.31003\/USPNF_M8286_02_01.","DOI":"10.31003\/USPNF_M8286_02_01"},{"key":"3393_CR28","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1248\/cpb.38.3452","volume":"38","author":"T Hatanaka","year":"1990","unstructured":"Hatanaka T, Inuma M, Sugibayashi K, Morimoto Y. Prediction of skin permeability. I. Comparison with artificial membrane. Chem Pharm Bull. 1990;38:3452\u20139.","journal-title":"Chem Pharm Bull"},{"key":"3393_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s13318-018-0460-3","volume":"43","author":"W Cawello","year":"2018","unstructured":"Cawello W, Braun M, Andreas JO. Drug delivery and transport into the central circulation: an example of zero-order in vivo absorption of rotigotine from a transdermal patch formulation. Eur J Drug Metab Pharmacokinet. 2018;43:475\u201381.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3393_CR30","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/jps.2600531126","volume":"53","author":"JG Wagner","year":"1964","unstructured":"Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci. 1964;53:1392\u2013403.","journal-title":"J Pharm Sci"},{"key":"3393_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jconrel.2015.05.263","volume":"210","author":"Y Yang","year":"2015","unstructured":"Yang Y, Manda P, Pavurala N, Khan MA, Krishnaiah YSR. Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems. J Control Release. 2015;210:58\u201366.","journal-title":"J Control Release"},{"key":"3393_CR32","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1124\/dmd.109.027383","volume":"37","author":"W Cawello","year":"2009","unstructured":"Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos. 2009;37:2055\u201360.","journal-title":"Drug Metab Dispos"},{"key":"3393_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40261-013-0150-5","volume":"34","author":"W Cawello","year":"2014","unstructured":"Cawello W, et al. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. Clin Drug Investig. 2014;34:95\u2013105.","journal-title":"Clin Drug Investig"},{"key":"3393_CR34","unstructured":"European Medicines Agency. Neupro: Scientific Discussion; European Public Assessment Report; 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/neupro-epar-scientific-discussion_en.pdf."},{"issue":"5","key":"3393_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1208\/s12249-019-1362-7","volume":"20","author":"R Sheshala","year":"2019","unstructured":"Sheshala R, Anuar NK, Abu Samah NH, Wong TW. In vitro drug dissolution\/permeation testing of nanocarriers for skin application: a comprehensive review. AAPS PharmSciTech. 2019;20(5):186.","journal-title":"AAPS PharmSciTech."},{"key":"3393_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111978","volume":"206","author":"CCB Ara\u00fajo","year":"2021","unstructured":"Ara\u00fajo CCB, Simon A, Hon\u00f3rio TS, da Silva SVC, Valle IMM, da Silva LCRP, Rodrigues CR, de Sousa VP, Cabral LM, Sathler PC, do Carmo FA. Development of rivaroxaban microemulsion-based hydrogel for transdermal treatment and prevention of venous thromboembolism. Colloids Surf B Biointerfaces. 2021;206:111978.","journal-title":"Colloids Surf B Biointerfaces."},{"issue":"10","key":"3393_CR37","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1021\/acs.molpharmaceut.4c00459","volume":"21","author":"M Railic","year":"2024","unstructured":"Railic M, Crean AM, Vucen S. Unravelling microarray patch performance: the role of in vitro release medium and biorelevant testing. Mol Pharm. 2024;21(10):5028\u201340.","journal-title":"Mol Pharm."},{"issue":"7","key":"3393_CR38","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1023\/A:1018954420874","volume":"10","author":"JH Kou","year":"1993","unstructured":"Kou JH, Roy SD, Du J, Fujiki J. Effect of receiver fluid pH on in vitro skin flux of weakly ionizable drugs. Pharm Res. 1993;10(7):986\u201390.","journal-title":"Pharm Res."},{"key":"3393_CR39","doi-asserted-by":"crossref","unstructured":"Akula P, Lakshmi PK. Effect of pH on weakly acidic and basic model drugs and determination of their ex vivo transdermal permeation routes. Braz J Pharm Sci. 2018;54:(2)1\u20138.","DOI":"10.1590\/s2175-97902018000200070"},{"issue":"1","key":"3393_CR40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1208\/s12248-008-9010-2","volume":"10","author":"RA Lionberger","year":"2008","unstructured":"Lionberger RA. FDA critical path initiatives: opportunities for generic drug development. AAPS J. 2008;10(1):103\u20139.","journal-title":"AAPS J"},{"issue":"2","key":"3393_CR41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijpharm.2017.11.038","volume":"544","author":"SH Choi","year":"2018","unstructured":"Choi SH, Wang Y, Conti DS, Raney SG, Delvadia R, Leboeuf AA, Witzmann K. Generic drug device combination products: Regulatory and scientific considerations. Int J Pharm. 2018;544(2):443\u201354.","journal-title":"Int J Pharm."},{"key":"3393_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejps.2005.10.007","volume":"27","author":"DM D\u2019Arcy","year":"2006","unstructured":"D\u2019Arcy DM, Corrigan OI, Healy AM. Evaluation of hydrodynamics in the basket dissolution apparatus using computational fluid dynamics: dissolution rate implications. Eur J Pharm Sci. 2006;27:259\u201367.","journal-title":"Eur J Pharm Sci."},{"key":"3393_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14227\/DT140107P6","volume":"14","author":"S Vangani","year":"2007","unstructured":"Vangani S, Flick T, Tamayo G, Chiu R, Cauchon N. Vibration measurements on dissolution systems and effects on dissolution of prednisone tablets RS. Dissolut Technol. 2007;14:6\u201314.","journal-title":"Dissolut Technol."},{"key":"3393_CR44","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1208\/s12249-015-0356-3","volume":"16","author":"N Seeger","year":"2015","unstructured":"Seeger N, Lange S, Klein S. Impact of vibration and agitation speed on dissolution of USP prednisone tablets RS and various IR tablet formulations. AAPS PharmSciTech. 2015;16:759\u201366.","journal-title":"AAPS PharmSciTech."},{"key":"3393_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2024.124209","volume":"658","author":"C Sirasitthichoke","year":"2024","unstructured":"Sirasitthichoke C, Patel S, Reuter KG, Hermans A, Bredael G, Armenante PM. Effect of basket mesh size on the hydrodynamics of a partially filled (500 mL) USP rotating basket dissolution testing apparatus 1. Int J Pharm. 2024;658:1\u201316.","journal-title":"Int J Pharm."},{"key":"3393_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijpharm.2011.03.051","volume":"418","author":"J Siepmann","year":"2011","unstructured":"Siepmann J, Peppas NA. Higuchi equation: derivation, applications, use and misuse. Int J Pharm. 2011;418:6\u201312.","journal-title":"Int J Pharm."},{"key":"3393_CR47","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/pr10061094","volume":"10","author":"P Trucillo","year":"2022","unstructured":"Trucillo P. Drug carriers: a review on the most used mathematical models for drug release. Processes. 2022;10:1094.","journal-title":"Processes."},{"key":"3393_CR48","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261\u20138.","journal-title":"Nat Biotechnol."},{"key":"3393_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1023\/A:1015826205930","volume":"8","author":"VP Shah","year":"1991","unstructured":"Shah VP, Elkins J, Hanus J, Noorizadeh C, Skelly JP. In vitro release of hydrocortisone from topical preparations and an automated procedure. Pharm Res. 1991;8:55\u20139.","journal-title":"Pharm Res."},{"key":"3393_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ddr.21427","volume":"79","author":"S Jacob","year":"2018","unstructured":"Jacob S, Nair AB. An updated overview with simple and practical approach for developing in vitro\u2013in vivo correlation. Drug Dev Res. 2018;79:1\u201310.","journal-title":"Drug Dev Res."},{"key":"3393_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.onano.2025.100245","volume":"24","author":"A Crasta","year":"2025","unstructured":"Crasta A, Painginkar T, Sreedevi A, Pawar SD, Badamane Sathyanarayana M, Vasantharaju SG, et al. Transdermal drug delivery system: a comprehensive review of innovative strategies, applications, and regulatory perspectives. OpenNano. 2025;24:100245.","journal-title":"OpenNano."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03393-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03393-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:03:14Z","timestamp":1790276594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03393-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3393"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03393-8","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author(s) confirm that this study content has no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"217"}}